Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions around this article use confident and precise language, such as 'confirms its superiority' and 'supports nivolumab plus ipilimumab as effective,' reflecting strong agreement. The tone and focus on detailed survival rates and clinical implications suggest high interest, deep engagement, and recognition of substantial impact on lung cancer treatment paradigms.
Many discussions highlight positive outcomes and endorse immunotherapy as a superior option, with phrases like 'confirms its superiority' and 'supports nivolumab plus ipilimumab as effective,' indicating strong consensus.
Posts reflect high curiosity through keywords like 'significant improvements,' 'five-year survival,' and references to detailed data, suggesting strong relevance and engagement.
Several posts delve into specifics, such as 5-year survival rates and PD-L1 status, and include citations of study presentations, demonstrating deep analysis and active participation.
The discussions emphasize the potential for changing clinical practice, with remarks that the findings 'support' and 'confirm' the effectiveness of these treatments, indicating they perceive meaningful influence on future oncology approaches.
肺癌イピニボのCheckMate-227。これ見るとPD-L1<1%ってのは抗PD-1抗体にとっては不利な腫瘍だが、抗CTLA-4抗体はむしろ低PD-L1という逆境を乗り越える力を抗PD-1抗体に与える感じだな。やっぱ食道癌で「PD-L1陽性はイピニボ」という論調がしばしば出るのは変に感じる。 ／JCO https://t.co/QmaaXufJx4
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/Hp7wLnX7uy
②CheckMate227試験（Nivo+Ipi vs Chemo）
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/Zip1enlhem
For more information visit httpsascopubsorgdoifull101200JCO2201503
This video reviews five-year survival results comparing Nivolumab and Ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer, highlighting recent clinical findings.
RT @m0370: 肺癌イピニボのCheckMate-227。これ見るとPD-L1<1%ってのは抗PD-1抗体にとっては不利な腫瘍だが、抗CTLA-4抗体はむしろ低PD-L1という逆境を乗り越える力を抗PD-1抗体に与える感じだな。やっぱ食道癌で「PD-L1陽性はイピニボ」と…
②CheckMate227試験（Nivo+Ipi vs Chemo）
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @dipeshuprety4: CheckMate-227: 5-year OS rates were 24% and 19% for PD-L1 ≥ 1% and PD-L1 < 1% with Nivo-Ipi https://t.co/BkOe3chj3g
CheckMate-227: 5-year OS rates were 24% and 19% for PD-L1 ≥ 1% and PD-L1 < 1% with Nivo-Ipi https://t.co/BkOe3chj3g
RT @cancer_evolve: LUNG: first line chemo-free immunotherapy treatment has delivered clinically meaningful improvements in 5 year survival…
LUNG: first line chemo-free immunotherapy treatment has delivered clinically meaningful improvements in 5 year survival rates, irrespective of PDL1 status or histology (adeno vs squamous). https://t.co/cZVYfjk1Zr
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/Hp7wLnX7uy
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/Zip1enlhem
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/xQl0Bdc25W #Oncology
6. 5-yr update of CheckMate-227: With Nivo plus Ipilimumab, 5-yr OS rates ➡️ 24% for PD-L1 ≥ 1% ➡️19% for PD-L1 < 1% https://t.co/t5OQsjq1mN
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/UmMf8PN7bi
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/bFnS8VinIg
RT @gedefo_sefh: Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–…
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 https://t.co/EEwXbsOux9
RT @JCO_ASCO:
RT @MLPOncoData: Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-…
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
RT @JCO_ASCO:
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227 https://t.co/6c8U4Zx33V
RT @JCO_ASCO:
RT @JCO_ASCO:
Confermata ancora una volta (con dati, come si dice, "maturi") la superiorità dell'immunoterapia (NIVOLUMAB + IPILIMUMAB) rispetto alla chemio nel trattamento di prima linea del cancro al polmone non a piccole cellule metastatico. https://t.co/FTVVem1IKK
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. https://t.co/WFfWcoBguG @JCO_ASCO https://t.co/vA5ENFe3Ui
肺癌イピニボのCheckMate-227。これ見るとPD-L1<1%ってのは抗PD-1抗体にとっては不利な腫瘍だが、抗CTLA-4抗体はむしろ低PD-L1という逆境を乗り越える力を抗PD-1抗体に与える感じだな。やっぱ食道癌で「PD-L1陽性はイピニボ」という論調がしばしば出るのは変に感じる。 ／JCO https://t.co/QmaaXufJx4
A recent study by @JulieBrahmer et colleagues supports nivolumab plus ipilimumab as an effective first-line treatment for patients with metastatic NSCLC https://t.co/8PeC14EZRM
https://t.co/cIgJJKyIsF
New article: Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227 https://t.co/X9YmNarPdb #lungcancer #oncology https://t.co/Ryyfq0sIDn
Join @JulieBrahmer presenting results from CheckMate 227: Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small cell #lungcancer @bmsnews #ASCO22 Hall A starting 8 am